MAYNE Pharma has
announced the US Food and
Drug Administration approval of
enteric coated antibacterial Doryx
MPC (doxycycline hyclate delayed
release tablets).
A tetracycline-class product, one
of the common uses of Doryx is in
severe acne treatment.
It orginally started life as a lower
urinary tract generic therapy
owned by Pfizer who marketed
the same product as Vibramycin
primarily for respiratory conditions.
The potential for Doryx in the US
is highlighted by the fact that acne
is the most prevalent skin disease
affecting around 45 million people
of all ages, Mayne has said.The above article was sent to subscribers in Pharmacy Daily's issue from 25 May 16 To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 25 May 16
RESPONDING to the findings from the Royal Commission into Aged Care Quality and Safety, a recent government initiative aims to improve medication management in residential aged care facilities by introducing on-site pharmacists.
RESEARCHERS at Charles Darwin University (CDU) are advancing a novel drug delivery system that could potentially eliminate the need for injections to treat various chronic diseases.
FREE Pharmacy Daily subscription - never miss another story!
to top
Subscribe to Pharmacy Daily
Pharmacy Daily subscription confirmation
Thank you for signing up! Check your email inbox – you should shortly receive a message with a link which must be clicked to confirm your subscription.
Once you’ve done that you will begin receiving Pharmacy Daily as soon as the next issue is published.